CN 23 ANAPHY LEC

1D-MT 3rd Shifting Journal Case Study

H, SKK. 11/30/2018
CN 23 ANAPHY LEC
1D-MT 3rd Shifting Journal Case Study
H, SKK. 11/30/2018
CN 23 ANAPHY LEC
1D-MT 3rd Shifting Journal Case Study
H, SKK. 11/30/2018
CN 23 ANAPHY LEC
1D-MT 3rd Shifting Journal Case Study
H, SKK. 11/30/2018
CN 23 ANAPHY LEC
1D-MT 3rd Shifting Journal Case Study
H, SKK. 11/30/2018
CN 23 ANAPHY LEC
1D-MT 3rd Shifting Journal Case Study
H, SKK. 11/30/2018
CN 23 ANAPHY LEC
1D-MT 3rd Shifting Journal Case Study
H, SKK. 11/30/2018

Usefulness of Measuring Serum Procalcitonin Levels in Patients with

Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) and intestinal Behcet’s disease (BD) are
both chronic conditions that involve inflammation of the gut or bowel characterized
by relapse and ulceration in general. The objective of the study is to evaluate the
usefulness of serum procalcitonin, a biomarker for infection and inflammation, in
determining the disease activity and severity or stage of infection in patients with
IBD and BD.

The study involved data taken from 129 patients with IBD and intestinal BD in
which the levels of their serum procalcitonin and C-reactive protein (CRP), also a
biomarker for determining infection, were measured from 2006 up to 2013.
Procalcitonin is an acute phase protein whose levels increase in response to
inflammatory stimuli such as infections that can be measured quickly and therefore
easily as compared to the traditional markers such as CRP, leukocytes, etc. which is
why it is the chosen marker for the study in the detection of bacterial infections and
sepsis in relation to inflammatory bowel disease. The serum procalcitonin levels
were determined and measured by the use of a commercially available enzyme-
linked assay.

Although the CRP and serum calcitonin levels in patients with BD and IBD did
not differ significantly as much when based on disease activity, it was found that
there was an increase in serum procalcitonin levels among these patients when
based on the stage or severity of the infection. There were three stages mentioned:
no infection, localized infection, and septic shock/sepsis in which the median levels
of serum procalcitonin among the patients increased as the condition of the disease
became worse in which the data were 0.21 ng/mL, 0.23 ng/mL, and 13.57 ng/mL
respectively.
CN 23 ANAPHY LEC
1D-MT 3rd Shifting Journal Case Study
H, SKK. 11/30/2018

It may be concluded that serum procalcitonin levels can be useful as a good

marker for detection of bacterial infection or sepsis as their levels do increase
depending on the severity of infection. However, it may only be significant when
sepsis, the highest or most severe case of infection, is present because only then
would the levels of serum procalcitonin be noticeably heightened as to compared
with only localized and no infection. The study also failed to widen its scale of
participants therefore the gathered data may be insufficient in firmly concluding the
findings. Lastly, the serum procalcitonin levels before and after antibiotic treatment
was implemented were not properly examined and compared therefore further study
upon the topic is recommended.